Epitomee Weight‑Management Capsule
Obesity
PreclinicalActive
Key Facts
About Epitomee Medical
A platform for pH‑triggered, biodegradable oral capsules that provide targeted GI therapy for chronic disease.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |
| Undisclosed siRNA Programs | Moonwalk Biosciences | Pre-clinical |